Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Awakn Life Sciences Corp (OP: AWKNF ) 0.0782 +0.0087 (+12.52%) Streaming Delayed Price Updated: 12:15 PM EDT, Jul 18, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Awakn Life Sciences Corp < Previous 1 2 3 4 5 Next > Psyched: Hawaii And Minnesota's Bills, Studying 2C-B Vs. Psilocybin, Filament CEO, Plus Brock Pierce And Jeremy Gardner Discuss The Industry's Future And More February 27, 2023 Two Bills Approved By Hawaii Senators With Governor's Endorsement Hawaii Senate Ways and Means Committee approved a pair of bills aiming to promote and investigate the therapeutic potential of MDMA and... Via Benzinga Awakn's First Licensing Partnership Deal In Europe Involves Chain Of Portuguese Clinics February 22, 2023 Awakn Life Sciences Corp. (OTCQB: AWKNF) has signed a licensing partnership agreement in Europe with a Portugal-based healthcare consortium currently operating in stealth mode. Via Benzinga Psyched: Four New States With Reform Bills, Psilocybin For Genetic Disorders And Functional Neurological Disorder, Struggle For Access & More February 21, 2023 Psychedelics States Reform: Utah, Iowa, Missouri and Oklahoma’s New Bills; Hawaii, Arizona and Washington's Green Lights, New Hampshire's Setback Earlier this week, three bills were introduced and... Via Benzinga Psychedelics For Alcohol Use Disorder: Awakn Opens European Clinic, FSD Launches R&D Program February 14, 2023 Awakn Opens Fourth European Clinic, Norway Takes Center Stage Via Benzinga Psyched: 12 States Discuss Legalization Bills, Ceremonies For Veterans With TBI, Ketamine And MDMA Fast-Tracks & More February 13, 2023 Psychedelics Legislation: The Latest On Hawaii, Virginia, Missouri & More Via Benzinga A New Way Of Delivering MDMA? Awakn And Tech Partner Are Set To Study Viability February 09, 2023 Psychedelics biotech Awakn Life Sciences (OTCQB: AWKNF) has initiated a feasibility study of formulating and delivering MDMA through Catalent’s proprietary oral, Via Benzinga Awakn Life Sciences Corp Shares Rally 77% After Earning ILAP Expedited Approval Pathway For Its Ketamine-Assisted AUD Therapeutic ($AWKNF) February 09, 2023 Via AB Newswire Exposures Product Safety Awakn's Ketamine Treatment For Alcohol Use Disorder Awarded UK's Fast-Track Status February 07, 2023 Awakn Life Sciences Corp. (OTCQB: AWKNF), a biotech company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), has been granted an Innovation Passport for... Via Benzinga Awakn Life Sciences Corp Earns Global AUD Treatment Interest With A New Class Of Psychedelics-Based Therapeutic ($AWKNF) February 07, 2023 Via AB Newswire Two New Studies On Classical Psychedelics: Grading Ketamine's Components, Tuning Down Psilocybin Dosing January 24, 2023 Awakn’s First Study On Novel S-Ketamine Formulation To Assess Dissociative Effect Via Benzinga What Happened With Psychedelics In The Last Year? 11 Key News Items, The Sector's Performance & Takeaways January 03, 2023 What a year for psychedelics! Via Benzinga 6 Largest Psychedelic Drug Stocks Were -20% In December January 02, 2023 The Psychedelic Drug Stocks Index, which tracks the six largest psychedelic stocks researching the treatment of mental illnesses based on the use of one or more psychedelic substances, continued to... Via Talk Markets Largest Psychedelic Stocks DOWN 8% Last Week; DOWN 22% So Far This Month December 25, 2022 Today's article highlights the performance of the munKNEE Psychedelic Drug Stocks Index which tracks the six (6) largest psychedelic stocks researching the treatment of mental illnesses based on the... Via Talk Markets Psyched: First Ayahuasca Pill Created, Psychedelics Legalization Predicted, UK's Research Support And More December 19, 2022 Ayahuasca Pill Is Officially Here, Filament CEO Discusses Future Plans The first medical-grade drug candidate of the psychedelic ayahuasca is being developed. Via Benzinga Awakn Unveils Q3 Results, Touts Revenue Growth, R&D Progress, Commercial Plans December 16, 2022 Psychedelics biotech Awakn Life Sciences Corp. (OTCQB: AWKNF) shared its financial results and business highlights for a three-month period that ended Oct. 31, 2022. Financials showed: Via Benzinga UK Supports Psychedelic Research With Phase 3 Trial In Federal Health Sites December 13, 2022 Awakn Life Sciences Corp. Via Benzinga Major Psychedelic Drug Stocks DOWN 9% Last Week; Now Down 51% YTD December 11, 2022 Today's article highlights the performance of the largest psychedelic stocks that research the treatment of a variety of mental illnesses based on the use of ten (10) different psychedelic substances. Via Talk Markets Psyched: Fed Guidelines And Research Production Quotas, Protests In Canada, Cal's Decrim Project December 06, 2022 Psychedelic Research & Fed Funding By The National Institute Of Mental Health The National Institute of Mental Health (NIMH) named the types of psychedelics studies to which it would grant funds and... Via Benzinga Europe To Have Expanded Access To Psychedelic-Assisted Therapy With New Norway Clinic December 03, 2022 Psychedelics biotech Awakn Life Sciences Corp. Via Benzinga Psyched: Full-Dose & Microdosing LSD Studies, Research Scope For Fed Funding, Consumption Sites And More November 29, 2022 LSD Research Ramps Up: Full-Dose & Microdosing For Alzheimer's Studies Led By Beckley Foundation Coming Soon Via Benzinga Psychedelic Drug Stocks Index Has A Good Week November 27, 2022 We track six psychedelic stocks researching the treatment of a variety of mental illnesses based on the use of 10 different psychedelic substances. Via Talk Markets A Leading Ketamine Treatment Clinic For Alcoholism Is Expanding: Here's The Latest November 23, 2022 A psychedelics R&D biotech company, known for providing novel treatments for addictions, is opening a new ketamine clinic. Via Benzinga Psychedelic Drug Stocks Index Continued To Decline Last Week November 20, 2022 This article highlights the performances of the 6 constituents in the munKNEE Psychedelic Drug Stocks Index last week and in the last 3 weeks and the extent to which each company is likely to encounter... Via Talk Markets Psyched: Colorado Legalizes Psychedelics, NYC Treats Alcoholism With Ketamine, $30M Series A For Startup November 15, 2022 Colorado Voters Approve Initiative To Legalize And Regulate Psychedelics Via Benzinga EXCLUSIVE: New Partnership Brings Leading Psychedelic Protocol For Alcoholism Treatment To NYC November 09, 2022 NYC-based clinics brand Nushama has partnered with Awakn Life Sciences (OTCQB: AWKNF), a clinical-stage psychedelics biotech company to bring Via Benzinga Can Ketamine Treat Alcohol Addiction? In-Clinic Therapy Vs. Retreats October 13, 2022 (Part four of a four-part series - Read part three) Via Benzinga Can Ketamine Treat Alcohol Addiction? The Awakn Approach October 10, 2022 (Part three of a four-part series) Via Benzinga Psychedelic Drug Stocks Index Up Slightly This Week October 08, 2022 There are 8 stocks in the munKNEE Psychedelic Drug Stocks Index and this article reveals how its constituents performed this week, in descending order, since the end of August and YTD. Via Talk Markets Can Ketamine Treat Alcohol Addiction? How Therapy Actually Functions? October 03, 2022 (Part two of a four-part series) Via Benzinga Can Ketamine Treat Alcohol Addiction? Clinics & Hospitals In Europe And North America Are Already Doing It September 30, 2022 (Part one of a four-part series) The use of psychedelic-assisted psychotherapy for the treatment of mental health conditions has become a hot topic, with a growing general sense of acceptance, public... Via Benzinga < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.